Bevacizumab (BVZ) as second-line treatment after sorafenib (SFB) progression in patients (pts) with advanced hepatocellular carcinoma (HCC)

Abstract only

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 28; no. 15_suppl; p. e14619
Main Authors Pazo Cid, R. A., Esquerdo, G., Puertolas, T., Calderero, V., Gil, I., Lao, J., Millastre, E., Alvarez-Alejandro, M., Madani, J., Anton, A.
Format Journal Article
LanguageEnglish
Published 20.05.2010
Online AccessGet full text

Cover

More Information
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2010.28.15_suppl.e14619